2 - 3 gange den systemiske eksponering (AUC eller Cmax) der er observeret hos nyretransplanterede patienter der fik den anbefalede kliniske dosis på 2 g daglig.
The highest dose tested in the animal carcinogenicity studies resulted in approximately 2 – 3 times the systemic exposure (AUC or Cmax) observed in renal transplant patients at the recommended clinical dose of 2 g/ day.